171 related articles for article (PubMed ID: 24733348)
1. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.
Brioli A; Giles H; Pawlyn C; Campbell JP; Kaiser MF; Melchor L; Jackson GH; Gregory WM; Owen RG; Child JA; Davies FE; Cavo M; Drayson MT; Morgan GJ
Blood; 2014 May; 123(22):3414-9. PubMed ID: 24733348
[TBL] [Abstract][Full Text] [Related]
2. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
3. Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma.
Patel UH; Drabick JJ; Malysz J; Talamo G
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e515-e519. PubMed ID: 30201257
[TBL] [Abstract][Full Text] [Related]
4. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
6. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
Avivi I; Cohen YC; Joffe E; Benyamini N; Held-Kuznetsov V; Trestman S; Terpos E; Dimopoulos MA; Kastritis E
Hematol Oncol; 2017 Dec; 35(4):734-740. PubMed ID: 27641057
[TBL] [Abstract][Full Text] [Related]
7. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
Mösbauer U; Ayuk F; Schieder H; Lioznov M; Zander AR; Kröger N
Haematologica; 2007 Feb; 92(2):275-6. PubMed ID: 17296589
[TBL] [Abstract][Full Text] [Related]
8. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.
Drayson M; Begum G; Basu S; Makkuni S; Dunn J; Barth N; Child JA
Blood; 2006 Sep; 108(6):2013-9. PubMed ID: 16728700
[TBL] [Abstract][Full Text] [Related]
9. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Radocha J; Pour L; Pika T; Maisnar V; Špička I; Gregora E; Krejčí M; Minařík J; Machálková K; Straub J; Pavlíček P; Hájek R; Žák P
Eur J Haematol; 2016 Feb; 96(2):119-27. PubMed ID: 25816709
[TBL] [Abstract][Full Text] [Related]
10. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
[TBL] [Abstract][Full Text] [Related]
11. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
Caillon H; Avet-Loiseau H; Attal M; Moreau P; Decaux O; Dejoie T
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e228-e237. PubMed ID: 30799237
[TBL] [Abstract][Full Text] [Related]
13. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains.
Pratt G; Mead GP; Godfrey KR; Hu Y; Evans ND; Chappell MJ; Lovell R; Bradwell AR
Leuk Lymphoma; 2006 Jan; 47(1):21-8. PubMed ID: 16321823
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
15. Appraisal of immunoglobulin free light chain as a marker of response.
Dispenzieri A; Zhang L; Katzmann JA; Snyder M; Blood E; Degoey R; Henderson K; Kyle RA; Oken MM; Bradwell AR; Greipp PR
Blood; 2008 May; 111(10):4908-15. PubMed ID: 18364469
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
Dispenzieri A; Kyle RA; Katzmann JA; Therneau TM; Larson D; Benson J; Clark RJ; Melton LJ; Gertz MA; Kumar SK; Fonseca R; Jelinek DF; Rajkumar SV
Blood; 2008 Jan; 111(2):785-9. PubMed ID: 17942755
[TBL] [Abstract][Full Text] [Related]
18. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
[TBL] [Abstract][Full Text] [Related]
19. Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD
Cancer; 2015 Mar; 121(6):853-62. PubMed ID: 25377852
[TBL] [Abstract][Full Text] [Related]
20. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
